Rudqvist, Nils-Petter http://orcid.org/0000-0002-9720-3124
Charpentier, Maud http://orcid.org/0000-0002-7343-4163
Lhuillier, Claire http://orcid.org/0000-0002-6846-1212
Wennerberg, Erik http://orcid.org/0000-0001-7689-5988
Spada, Sheila http://orcid.org/0000-0001-8644-2237
Sheridan, Caroline
Zhou, Xi Kathy http://orcid.org/0000-0002-8942-439X
Zhang, Tuo http://orcid.org/0000-0001-5396-918X
Formenti, Silvia C. http://orcid.org/0000-0002-8227-8924
Sims, Jennifer S.
Alonso, Alicia
Demaria, Sandra http://orcid.org/0000-0003-4426-0499
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA201246, R01CA198533, P30 CA08748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation (BCRF-22-053)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 1 November 2022
Accepted: 13 August 2023
First Online: 24 August 2023
Competing interests
: The authors declare that they have no competing interests related to this work. However, S.D. has received compensation for consultant/advisory services from Lytix Biopharma, EMD Serono, Ono Pharmaceutical, Genentech, and Johnson & Johnson Enterprise Innovation Inc., and research support from Lytix Biopharma, Nanobiotix, and Boehringer-Ingelheim for unrelated projects. S.C.F. is/has been holding research contracts with Merck, Varian, Bristol Myers Squibb, Celldex, Regeneron, Eisai, and Eli-Lilly, and has received consulting/advisory honoraria from Bayer, Bristol Myers Squibb, Varian, Elekta, Regeneron, Eisai, AstraZeneca, MedImmune, Merck US, EMD Serono, Accuray, Boehringer Ingelheim, Roche, Genentech, AstraZeneca, View Ray, and Nanobiotix.